psilocin

Tryptamine Therapeutics Ltd (OTC:TYPTF) has announced that its lead asset, TRP-8803, a psilocin-based IV infusion, will progress to Phase 2 clinical trials following a successful Phase 1b study. TRP-8803 demonstrated significant advantages over oral psilocybin, including rapid onset, precise...

The U.S. Food and Drug Administration (FDA) has offered positive feedback to CaaMTech, Inc. on its CT-4201 psilocin prodrug program, specifically endorsing the company's approach to addressing "functional unblinding" in its drug trials. This regulatory milestone not only clears the clinical...

Recent innovations in psychedelics research are laying the groundwork for a potential breakthrough in mental health treatments. The focus is on three new compounds patented by CaaMTech, Inc., designed to address the limitations of traditional psychedelics such as psilocybin and psilocin. According...

Michigan could soon become the latest state to allow the legal use of psychedelic mushrooms for individuals with post traumatic stress disorder (PTSD). As Marijuana Moment reported, a new bill introduced by State Rep. Mike McFall (D) proposes legalizing up to two ounces of psilocybin mushrooms for...

The UK-based psychedelics medicine company Beckley Psytech announced Thursday that it has dosed its first patients in a Phase IIa study (NCT05434156) of ELE-101, a patent-protected synthetic formulation of psilocin benzoate to treat major depressive disorder (MDD). Psilocin is the active metabolite...

Enveric Biosciences Inc. (NASDAQ:ENVB) said on Friday it has agreed to sell one of its cancer-related patent portfolios. The Cambridge, Massachusetts-based company didn't disclose the amount. The divested portfolio includes patents issued in the U.S., Australia, Canada, China, Europe and Japan,...

Biopharma R&D company Mindset Pharma Inc. (OTCQB: MSSTF) has performed preclinical screening studies and selected MSP-2020 as the lead psychedelic drug clinical candidate and MSP-2003 as the second backup drug candidate, both belonging to its Family 2 next-gen psychedelic drug program done in...

The World Intellectual Property Organization (WIPO) has published clinical-stage biopharma Tryp Therapeutics Inc. (OTCQB: TRYPF)’s international patent application for the intravenous (IV) administration of psilocybin and psilocin.  The “Improved Methods For The Use of Psychedelics...